The frequency of hematological malignancies is quite high in children, adolescents and young adults. Infertility after treatment is an important issue affecting the quality of life of long-term survivorsas the outcome of treatment is improved. Recently, several guidelines for infertility and fertility preservation have been published. Consequently, it has become easier to obtain information on the risk of infertility and fertility preservation therapy for each treatment. However, the information on the optimal timing for fertility preservation and current outcomes of assisted reproductive technology using stored oocytes, embryos, ovarian tissues, or sperm remains limited. Further, whether fertility preservation while using a new drug with unknown risk for infertility should be performed remains an unresolved issue.
Keywords: Fertility preservation; Hematologic malignancies; Infertility.